Skip to main content
SpringerLink
Log in

Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”

  • Letter to the Editor
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schoenfeld DA. Comment on “Progression-free survival as a surrogate for overall survival in clinical trials of targeted therapy of advanced solid tumors”. Drugs 2017. doi:10.1007/s40265-017-0760-y.

  2. Michiels S, Saad ED, Buyse M. Progression-free survival as a surrogate for overall survival in clinical trials of targeted therapy in advanced solid tumors. Drugs. 2017;77(7):713–9.

    Article  PubMed  Google Scholar 

  3. Schoenfeld DA, Finkelstein DM. Assessing survival benefit when treatment delays disease progression. Clin Trial. 2016;13(3):352–7.

    Article  Google Scholar 

  4. García-Albéniz X, Maurel J, Hernán MA. Why post-progression survival and post-relapse survival are not appropriate measures of efficacy in cancer randomized clinical trials. Int J Cancer. 2015;136(10):2444–7.

    Article  PubMed  Google Scholar 

  5. Mauguen A, Michiels S, Rondeau V. Joint model imputation to estimate the treatment effect on long-term survival using auxiliary events. J Biopharm Stat. 2017;16:1–11.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gustave Roussy, Service de Biostatistique et d’Epidémiologie, Villejuif, 94805, France

    Stefan Michiels

  2. Université Paris-Saclay, Université Paris-Sud, UVSQ, CESP, INSERM U1018, Villejuif, 94805, France

    Stefan Michiels

  3. Gustave Roussy, Ligue Nationale Contre le Cancer Meta-Analysis Platform, Villejuif, 94805, France

    Stefan Michiels

  4. International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium

    Everardo D. Saad

  5. Interuniversity Institute for Biostatistics and statistical Bioinformatics (I-BioStat), Hasselt University, Hasselt, Belgium

    Marc Buyse

  6. International Drug Development Institute (IDDI), San Francisco, CA, USA

    Marc Buyse

Authors
  1. Stefan Michiels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Everardo D. Saad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marc Buyse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Michiels.

Ethics declarations

Conflict of interest

Dr. Michiels declares no conflict of interest. Dr. Buyse reports being employed by, and holding stock in, the International Drug Development Institute, and Dr. Saad reports being employed by the International Drug Development Institute.

Additional information

This letter refers to the original article available at doi:10.1007/s40265-017-0728-y.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Michiels, S., Saad, E.D. & Buyse, M. Authors’ Reply to Schoenfeld: “Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors”. Drugs 77, 1139–1140 (2017). https://doi.org/10.1007/s40265-017-0761-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-017-0761-x

Search

Navigation